GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Locally Advanced Nasopharyngeal Carcinoma Clinical Trial

Official title:

A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03604965
• Other study ID #: 201805043
• Status: Recruiting
• Phase: Phase 3
• Start date: July 21, 2018
• Est. completion date: July 21, 2020

Study information

• Verified date: July 2018
• Source: Guiyang Medical University
• Contact: Feng Jin, Bachelor
• Phone: 0851-86512802
• Email: jinf8865[@]yeah.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Through randomized controlled phase III multicenter clinical trials, GP induction chemotherapy vs TPF regimen adjuvant chemotherapy combined with DDP concurrent chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and quality of life, and further improvement Survival rate and improve the quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 204
• Est. completion date: July 21, 2020
• Est. primary completion date: July 21, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

1. In the newly diagnosed patient, no radiotherapy or chemotherapy was performed before the start of the clinical trial.

2. Pathologically confirmed as non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated, ie WHO type II or III).

3. III, IVa patients (AJCC version 8 staging).

4. Male or non-pregnant women.

5. Age = 18 and < 70 years old.

6. Functional status: Karnofsky scale (KPS) > 70.

7. White blood cells (WBC) = 4 × 109.

/L, hemoglobin (HGB) = 90 g / L, platelets (PLT) = 100 × 109 / L (or within the normal range of the laboratory)

8. Liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 1.5 times the upper limit of normal (ULN); Total bilirubin = 1.5 × ULN.

9. Renal function: creatinine clearance = 60ml / min or serum creatinine = 1.5 × ULN.

10. The patient has signed an informed consent form.

Exclusion Criteria:

1. The pathological type is WHO's keratinized squamous cell carcinoma or basal squamous cell carcinoma.

2. Age = 70 years old or < 18 years old.

3. Treatment is palliative.

4. Previous history of malignant tumors, well-treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ outer.

5. Women during pregnancy or lactation (pregnant women should be considered for women of childbearing age; Effective contraception).

6. Previously received radiation therapy (if non-melanoma skin cancer and previous lesions are outside the target area of radiotherapy, then except).

7. Primary and cervical metastatic lesions received chemotherapy or surgery (except for diagnostic treatment).

8. With other serious diseases, it may bring greater risk or affect the compliance of the test. For example: no need for treatment Stable heart disease, kidney disease, chronic hepatitis, control of unsatisfactory diabetes (fasting blood glucose > 1.5 × ULN),And mental illness.

Related Conditions & MeSH terms

• Carcinoma
• Locally Advanced Nasopharyngeal Carcinoma
• Nasopharyngeal Neoplasms

Intervention

Drug:
• GP+CCRT
Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
• TPF+CCRT
Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy

Locations

Country	Name	City	State
China	Cancer Hospital of Guizhou Medical University	Guiyang	???

Sponsors (1)

Lead Sponsor	Collaborator
Guiyang Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progress-free survival(PFS)	Progress-free survival(year) is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.	3 years
Secondary	Overall survival(OS)	The OS(year) was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.	3 years
Secondary	Locoregional failure-free survival(LRFS)	The LRFS(year) is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.	3 years
Secondary	Distant metastasis-free survival(DMFS)	The DMFS(year) is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.	3 years
Secondary	Overall response rate	Tumour response(CR/PR/SD/PD) was classified according to RECIST v1.1	3 years
Secondary	Incidence of acute and late toxicity	Incidence of acute toxicity(Grade1/2/3/4) is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria. Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme	3 years